British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009

被引：344

作者：

Smith, C. H. ^{[1
]}

Anstey, A. V. ^{[2
]}

Barker, J. N. W. N. ^{[1
]}

Burden, A. D. ^{[3
]}

Chalmers, R. J. G. ^{[4
]}

Chandler, D. A. ^{[5
]}

Finlay, A. Y. ^{[6
]}

Griffiths, C. E. M. ^{[4
]}

Jackson, K. ^{[1
]}

McHugh, N. J. ^{[7
]}

McKenna, E. ^{[8
]}

Reynolds, N. J. ^{[9
]}

Ormerod, A. D. ^{[10
]}

机构：

[1] Kings Coll London & Guys & St Thomas NHS Fdn Trus, St Johns Inst Dermatol, London SE1 9RT, England

[2] Royal Gwent Hosp, Dept Dermatol, Newport NP20 2UB, Gwent, Wales

[3] Univ Glasgow, Western Infirm, Dept Dermatol, Glasgow G11 6NT, Lanark, Scotland

[4] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Salford M6 8HD, Lancs, England

[5] Psoriasis & Psoriat Arthrit Alliance, St Albans AL2 3JQ, England

[6] Cardiff Univ, Sch Med, Dept Dermatol, Cardiff CF14 4XN, S Glam, Wales

[7] Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England

[8] Belfast City Hosp, Dept Dermatol, Belfast BT9 7AB, Antrim, North Ireland

[9] Univ Newcastle, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[10] Aberdeen Royal Infirm, Dept Dermatol, Aberdeen AB9 2ZB, Scotland

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2009年 / 161卷 / 05期

关键词：

adalimumab; biologics; efalizumab; etanercept; guideline; infliximab; psoriasis; ustekinumab; TUMOR-NECROSIS-FACTOR; QUALITY-OF-LIFE; T-CELL LYMPHOMA; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; GENERALIZED PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; PATIENT-REPORTED OUTCOMES; FACTOR-ALPHA ANTAGONISTS; LONG-TERM TREATMENT; CHRONIC PLAQUE PSORIASIS;

D O I：

10.1111/j.1365-2133.2009.09505.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

[No abstract available]

引用

页码：987 / 1019

页数：33

共 229 条

[1]

*AGREE, 2004, AGREE INSTR

[2] Two years of experience with etanercept in recalcitrant psoriasis [J].

Ahmad, K. ;

Rogers, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) :1010-1014

[3]

ALLISON LS, 2007, ARTHRIT CARE RES, V57, P1431

[4]

[Anonymous], 2006, TUB CLIN DIAGN MAN T

[5]

[Anonymous], NICE CLIN GUID

[6]

[Anonymous], 2002, Br J Dermatol

[7] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [J].

Antoni, CE ;

Kavanagh, A ;

Kirkham, B ;

Tutuncu, Z ;

Burmester, GR ;

Schneider, U ;

Furst, DE ;

Molitor, J ;

Keystone, E ;

Gladman, D ;

Manger, B ;

Wassenberg, S ;

Weier, R ;

Wallace, DJ ;

Weisman, MH ;

Kalden, JR ;

Smolen, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1227-1236

[8]

Ashcroft DM, 1999, BRIT J DERMATOL, V141, P185

[9] Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection:: two cases [J].

Aslanidis, S. ;

Vassiliadis, T. ;

Pyrpasopoulou, A. ;

Douloumpakas, I. ;

Zamboulis, C. .

CLINICAL RHEUMATOLOGY, 2007, 26 (02) :261-264

[10] Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis [J].

Asumalahti, K ;

Ameen, M ;

Suomela, S ;

Hagforsen, E ;

Michaëlsson, G ;

Evans, J ;

Munro, M ;

Veal, C ;

Allen, M ;

Leman, J ;

Burden, AD ;

Kirby, B ;

Connolly, M ;

Griffiths, CEM ;

Trembath, RC ;

Kere, J ;

Saarialho-Kere, U ;

Barker, JNWN .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (04) :627-632

← 1 2 3 4 5 6 7 8 9 10 →